[Research Advances on BK Virus Associated Hemorrhagic Cystitis after HSCT-Review]

Area of Science:

• Urology
• Hematology
• Virology

Background:

• BK virus (BKV) associated hemorrhagic cystitis is a frequent and severe complication post-hematopoietic stem cell transplantation (HSCT).
• This condition significantly impacts patient morbidity and mortality, yet clinical attention and effective management strategies remain insufficient.
• There is a critical need for precise BKV monitoring and advanced therapeutic interventions.

Purpose of the Study:

• To review recent advancements in understanding and managing BKV-associated hemorrhagic cystitis following HSCT.
• To highlight the clinical utility of BKV-DNA monitoring in early detection and management.
• To discuss emerging therapeutic strategies beyond traditional antiviral agents.

Main Methods:

• Literature review of recent studies on BKV pathogenesis, diagnosis, and treatment after HSCT.
• Analysis of the clinical value of BKV-DNA monitoring techniques.
• Evaluation of current and novel therapeutic approaches, including cidofovir and virus-specific lymphocytes.

Main Results:

• BKV-DNA monitoring demonstrates significant clinical value in managing BKV-associated hemorrhagic cystitis post-HSCT.
• Traditional antiviral treatments like cidofovir show limited efficacy.
• Emerging therapies, such as virus-specific lymphocytes, offer promising alternatives.

Conclusions:

• Accurate and timely BKV monitoring is essential for effective management of post-HSCT hemorrhagic cystitis.
• Novel therapeutic strategies are needed to improve outcomes for patients with BKV infection.
• Continued research into BKV pathogenesis and treatment is vital for this vulnerable patient population.